Thus, we surmise that the protective effect of SA on NAFLD might be explained by the remodeling of gut microbiota composition and the production of LPS and SCFAs, counteracting hepatic TLR-4/NF-κB/NLRP3 pathway-mediated inflammation. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.